HIV mutation literature information.


  Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.
 PMID: 11408240       2001       Antimicrobial agents and chemotherapy
Abstract: RT from site-directed mutants with 69S-XX codon insertions and/or conventional zidovudine resistance mutations seems to be involved in an ATP-dependent resistance mechanism analogous to pyrophosphorolysis, whereas the mechanism for RT with the Q151M or V75T mutation appears to be independent of added ATP for reducing binding to d4T-triphosphate.


  Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.
 PMID: 11417763       2001       Antiviral therapy
Abstract: No patients displayed the multi-nucleoside resistance Q151M mutation.


  Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.
 PMID: 11435603       2001       Journal of virology
Abstract: The ATP-dependent mechanism (analogous to pyrophosphorolysis) appears to be dominant in the mutants bearing the D67N and K70R or 69 insertion mutations, whereas the Q151M mutation seems independent of ATP for decreased binding to AZT-triphosphate.


  HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.
 PMID: 11506064       2001       Microbios
Abstract: In the present study three out of 350 (0.85%) of HIV-infected patients who underwent a drug-resistance genotyping assay because of therapeutic failure showed the Q151M mut.
Abstract: One such patient failed to respond to all salvage regimens tried and was shown to harbour some of the characteristic mut associated with Q151M (77L and 116Y).
Abstract: The M184V mut seemed to confer some viro-immunological benefit when associated with the Q151M mutation, compared with the latter alone.


  Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
 PMID: 11522180       2001       AIDS research and human retroviruses
Abstract: Of these, 24 samples (28%) had TAMs, and 30 samples (35%) had either TAMs and/or the Q151M multinucleoside resistance (MNR) mutation.


  Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.
 PMID: 11559430       2001       AIDS research and human retroviruses
Abstract: In a subsequent sample 3 months later additional RT mutations were found, including A62V, Y188L, and Q151M, conferring high-level cross-resistance to multiple nucleoside analogs.


  Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
 PMID: 11562951       2001       Nucleosides, nucleotides & nucleic acids
Abstract: Tenofovir is uniquely active against multinucleoside-resistant HIV expressing the Q151M mutation, but shows reduced susceptibility to the T69S insertion mutations.


  Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a cohort of Italian HIV-1 seropositive patients extensively treated with antiretroviral drugs.
 PMID: 11738338       2001       International journal of antimicrobial agents
Abstract: Results showed the presence of one or more mutations (A62V, V75I, F77L, F116Y and Q151M) able to confer resistance to all NRTIs in a relatively high percentage (7.9%) of patients enrolled in the study.


  Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
 PMID: 11808752       2001       Antiviral therapy
Abstract: A recent genotypic study in naive patients receiving stavudine/didanosine combination showed emergence of TAMs and a multidrug-resistance mutation (MDR), Q151M, in 36 and 10% of cases, respectively.
Abstract: CONCLUSIONS: Our study clearly demonstrated that naive subjects treated with stavudine/lamivudine for 24-48 weeks selected a low rate of TAMs and MDR Q151M.
Abstract: Only two subjects (4.5%) developed a TAM (T215Y; M41L), one subject developed a V75T/A mutation and one subject developed the particular MDR pattern F116Y, Q151M.


  Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay.
 PMID: 11907381       2001       Journal of human virology
Abstract: Q151M mutants were detected as minor populations (13%-24%) by OLA but not by sequencing in 4 samples.



Browser Board

 Co-occurred Entities




   Filtrator